Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

PIALOUX

Showing results (371-380 of 578) with videos related to

Pageof 58
Sort By:
Annales De Dermatologie Et De Venereologie|September 30, 2018
[The value of fecal calprotectin assay in chronic panniculitis of unknown etiology]K Kaddour, J Lemasson, B Haettich-Pialoux, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 1998
Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapyD David, L Bani, J L Moreau, et al.
The Lancet. Infectious Diseases|June 9, 2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialJose R Arribas, Gilles Pialoux, Joseph Gathe, et al.
The Journal of Infectious Diseases|October 1, 1996
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160B Fleury, G Janvier, G Pialoux, et al.
Open Forum Infectious Diseases|August 5, 2024
Prevalence and Risk Factors of Cytomegalovirus Among Men Having Sex With Men Enrolled in a Pre-Exposure Prophylaxis StudySylvain Chawki, Nicolas Leturque, Marine Minier, et al.
AIDS (London, England)|August 11, 2018
Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trialConstance Delaugerre, Christophe Rodriguez, Catherine Capitant, et al.
Experimental Physiology|December 6, 2019
Effects of hypoxia-reoxygenation stimuli on renal redox status and nuclear factor erythroid 2-related factor 2 pathway in sickle cell SAD miceCamille Faes, Gaëtan Juban, Emeline Aufradet, et al.
British Journal of Haematology|March 18, 2020
Alterations in vascular reactivity in a transgenic mouse model of sickle cell traitSarah Skinner, Kiao Ling Liu, Ming Lo, et al.
AIDS (London, England)|April 11, 2006
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitorsJean-Marie Poirier, Jean-Baptiste Guiard-Schmid, Jean-Luc Meynard, et al.
Lancet (London, England)|July 20, 1991
Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complexG Pialoux, M Youle, B Dupont, et al.
Pageof 58

Showing results (371-380 of 578) with videos related to

Sort By:
Pageof 58
Annales De Dermatologie Et De Venereologie|September 30, 2018
[The value of fecal calprotectin assay in chronic panniculitis of unknown etiology]K Kaddour, J Lemasson, B Haettich-Pialoux, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 1998
Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapyD David, L Bani, J L Moreau, et al.
The Lancet. Infectious Diseases|June 9, 2014
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trialJose R Arribas, Gilles Pialoux, Joseph Gathe, et al.
The Journal of Infectious Diseases|October 1, 1996
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160B Fleury, G Janvier, G Pialoux, et al.
Open Forum Infectious Diseases|August 5, 2024
Prevalence and Risk Factors of Cytomegalovirus Among Men Having Sex With Men Enrolled in a Pre-Exposure Prophylaxis StudySylvain Chawki, Nicolas Leturque, Marine Minier, et al.
AIDS (London, England)|August 11, 2018
Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trialConstance Delaugerre, Christophe Rodriguez, Catherine Capitant, et al.
Experimental Physiology|December 6, 2019
Effects of hypoxia-reoxygenation stimuli on renal redox status and nuclear factor erythroid 2-related factor 2 pathway in sickle cell SAD miceCamille Faes, Gaëtan Juban, Emeline Aufradet, et al.
British Journal of Haematology|March 18, 2020
Alterations in vascular reactivity in a transgenic mouse model of sickle cell traitSarah Skinner, Kiao Ling Liu, Ming Lo, et al.
AIDS (London, England)|April 11, 2006
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitorsJean-Marie Poirier, Jean-Baptiste Guiard-Schmid, Jean-Luc Meynard, et al.
Lancet (London, England)|July 20, 1991
Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complexG Pialoux, M Youle, B Dupont, et al.
Pageof 58